Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Darktrace investment case strengthening, claims analyst

Analysts have raised Darktrace (DARK) profit forecasts ahead of annual results set to be published on 6 September. Having revisited the investment case, Liberum has upgraded 2023 adjusted EBITDA (earnings before interest, tax, depreciation and amortisation) estimates by 14%, and nudged full year 2024 and 2025 adjusted EBITDA higher.
Describing Darktrace as the ‘Marmite’ of the UK tech sector, Liberum has been impressed with recent trading, believes the cybersecurity group’s products have got better over time and sees strong tailwinds for demand from rising cybercrime and new regulation.
The broker estimates that cybersecurity has doubled as a proportion of corporate IT spend over the last three years. ‘We have upgraded our adjusted EBITDA estimates by 14%, 5% and 4% for full year 2023, 2024 and 2025 respectively, having previously been 5% ahead of consensus,’ it says.
This largely reflects the guidance given in a trading update on 18 July, when Darktrace stated that it expects revenue of $544 million and an EBITDA margin of no less than 22%, compared to previous margin guidance of 19%, in 2023.
In July, Darktrace was given a clean bill of health after accounting firm EY was instructed to run an independent audit of its books. That news, combined with the trading update, propelled Darktrace shares nearly 30% higher across two days of high-volume trading.
Darktrace came under fire at the start of 2023 from New York-based short seller Quintessential Capital Management, an attack that had dragged on the share price for most of this year. That led to the EY report being commissioned.
The EY report flagged several areas where improvement work was needed, but nothing that would impact previous financial statements, nor anything to slow Grant Thornton’s audit of the financial year to 30 June 2023.
‘EY reported several areas where systems, processes or controls could be improved around its channel processes and controls, where it identified a small number of errors and inconsistencies,’ said Tom Kennedy, an analyst at Megabuyte.
Kennedy reflected that the report could have wider implications on broader market murmurings that ‘something wasn’t quite right’ at Darktrace. The investigation into the firm’s finances ‘has essentially proved that the cybersecurity expert doesn’t have any skeletons in the closet,’ said the analyst, and Liberum now seems to agree.
Liberum’s latest calculation suggest nearly 30% upside could be on the cards from Darktrace shares over the next 12 months, from the current 349p to its new target of 440p.
Palo Alto (PANW:NASDAQ), the world’s second largest cybersecurity vendor, saw its share price rise 15% on 21 August after reporting fourth quarter results which included a deep dive into its industry, noting that the number of cyber attacks and malicious programs is still on the rise.
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
Issue contents
Book reviews
Exchange-Traded Funds
Feature
Funds
Great Ideas
News
- Discover the reasons behind these three retail share price jitters
- Darktrace investment case strengthening, claims analyst
- August hasn’t been kind to stocks but investors find a silver lining
- Moderna shares surge on cancer venture and Biden booster plan
- Asset manager Abrdn is having a tough time on the stock market